BioStem Technologies, Inc. (BSEM)
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
BioStem Technologies, Inc.
1-25 of 73 filings
Recent SEC filings with analysis
- 424B3BioStem Technologies filed a 424B3 prospectus registering the resale of up to 2,224,270 common shares by selling stockholders from its September 2026 private…
- S-1BioStem Technologies filed an S-1 registering the resale of up to 2,224,270 shares by selling stockholders, tied to a September 29, 2026 private placement of…
- 8-KBioStem Technologies (BSEM) closed a ~$3.0 million private placement on September 30, 2026, selling 735,296 shares at $4.08 each to institutional investors,…
- 424B3BioStem Technologies filed a 424B3 prospectus registering the resale by Roth Principal Investments of up to 12,050,000 shares issuable under a $40 million…
- S-1BioStem Technologies filed an S-1 registering up to 12,050,000 shares of common stock for resale by Roth Principal Investments, LLC under a $40,000,000…
- 8-KBioStem Technologies entered into a common stock purchase agreement with Roth Principal Investments on September 18, 2026, establishing a $40 million committed…